Reynolds Carson R, Tran Son, Jain Mohit, Narendran Aru
Departments of Oncology and Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Vaccines (Basel). 2022 Jan 26;10(2):196. doi: 10.3390/vaccines10020196.
Alternatives to conventional cancer treatments are highly sought after for high-risk malignancies that have a poor response to established treatment modalities. With research advancing rapidly in the past decade, neoantigen-based immunotherapeutic approaches represent an effective and highly tolerable therapeutic option. Neoantigens are tumor-specific antigens that are not expressed in normal cells and possess significant immunogenic potential. Several recent studies have described the conceptual framework and methodologies to generate neoantigen-based vaccines as well as the formulation of appropriate clinical trials to advance this approach for patient care. This review aims to describe some of the key studies in the recent literature in this rapidly evolving field and summarize the current advances in neoantigen identification and selection, vaccine generation and delivery, and the optimization of neoantigen-based therapeutic strategies, including the early data from pivotal clinical studies.
对于那些对现有治疗方式反应不佳的高危恶性肿瘤,传统癌症治疗的替代方法备受追捧。在过去十年中,随着研究的迅速发展,基于新抗原的免疫治疗方法成为一种有效且耐受性良好的治疗选择。新抗原是正常细胞中不表达的肿瘤特异性抗原,具有显著的免疫原性潜力。最近的几项研究描述了生成基于新抗原的疫苗的概念框架和方法,以及开展适当临床试验以推进这种方法用于患者治疗的方案。本综述旨在描述该快速发展领域近期文献中的一些关键研究,并总结新抗原识别与选择、疫苗生成与递送以及基于新抗原的治疗策略优化方面的当前进展,包括关键临床研究的早期数据。